Abstract:Objective: Glanzmann's thrombasthenia (GT) is a rare autosomal recessive disorder, which characterized by the clinical manifestations from purpura to severe bleeding. It was caused by mutations of the ITGA2B or ITGB3 gene on chromosome 17, which lead to deficits or reduced expression of the platelet membrane glycoprotein GPIIb/IIIa. We report 5 pediatric patients with severe Glanzmann's thrombasthenia who underwent allogeneic hematopoietic stem cell transplant, to observe the outcomes of allo-HSCT in children with severe Glanzmann's thrombasthenia. Methods: We retrospectively summarized the clinical and genetic profiles of five patients with Glanzmann's thrombasthenia who underwent allo-HSCT from June 2021 to July 2023. All patients were reduced intensity conditioning (Bufulsan 3.2-6.4mg/kg, CTX 120mg/kg, FLU 180mg/m 2, ATG 10mg/kg). After conditioning chemotherapy, all the patients received stem cells collected via bone marrow harvest and/or peripheral blood apheresis (PBSC) with CD34 dose of 2.89-7.2×10 6/kg and received graft vs. host disease (GvHD) prophylaxis with cyclosporine (CSA) and methotrexate (MTX). Results: There were five children were involved in this observation, one patient suffered from recurrent epistaxis bleeding which was life-threatening; the second suffered from gastrointestinal bleeding and could only accept liquid diet to 10-years-old; other patients also suffered from epistaxis bleeding, gum bleeding or gastrointestinal bleeding. For all the patients, regular red cell transfusions were required, platelet transfusions and recombinant factor VIIa were also used in severe and life-threatening bleeding events. Two of the five developed antiplatelet antibodies before HSCT. All the patients were successfully treated with allo-HSCT. One case received non-relative matched donor of 10/10 HLA, one case with sibling matched donor, and 3 cases with haploid transplantation of HLA 5-6/10 matched. The mean time to neutrophil engraftment was 11 days (11-12 days), and the mean time to platelet engraftment was 16 days (15-18 days). One case had CMV reactivation, one case had HHV-6b infection, one case had grade II acute GVHD of the skin which was controlled rapidly. There was no evidence of chronic GVHD for all the patients. The platelet disorder was corrected to a normal level after allo-HSCT, with no significant complication related to the transplantation. Comparing with HLA matched donor, either from sibling or non-related, the patients receiving haploid transplantation with 5-6/10 HLA matched got similar outcome. Conclusions: We proposed haploid transplantation treated with the reduced intensity conditioning regimens produced similar outcomes as HLA matched did which could be recommended as an alternative donor for severe Glanzmann's thrombasthenia.

Modeling Glanzmann Thrombasthenia Using Patient Specific Ipscs and Restoring Platelet Aggregation Function by CD41 Overexpression.

Glanzmann Thrombasthenia 10 Years Later: Progress Made and Future Directions

Novel Homozygous Silent Mutation of ITGB3 Gene Caused Glanzmann Thrombasthenia

New Compound Heterozygous Mutations of GPIIb in Patient with Glanzmann Thrombasthenia.

Catheter Intervention in a Patient with Intracranial Aneurysms and Glanzmann Thrombasthenia Caused by a Novel Homozygous Likely Pathogenic Variant in the ITGA2B Gene

A Novel Pro126his Beta Propeller Mutation in Integrin Alpha Iib Causes Glanzmann Thrombasthenia by Impairing Progression of Pro-Alpha Iib Beta 3 from Endoplasmic Reticulum to Golgi

SINE-VNTR-Alu Retrotransposon Insertion As a Novel Mutational Event Underlying Glanzmann Thrombasthenia.

A Rare Glanzmann Thrombasthenia Pedigree of C.1067T>C Heterozygous Mutation in ITGA2B Gene

Analysis of Phenotype and Genotype in Eight Chinese Pedigrees with Glanzmann Thrombastheuia

[Molecular Analysis of Gene Mutations in Eight Patients with Glanzmann's Thrombasthenia].

Targeting tissue factor pathway inhibitor with concizumab to improve hemostasis in patients with Glanzmann thrombasthenia: an in vitro study

Successful Use of Haploid Hematopoietic Stem Cell Transplantation for Severe Glanzmann's Thrombasthenia

Clinical and Molecular Insights into Glanzmann's Thrombasthenia in China

Pathogenesis and prenatal diagnosis of hereditary Glanzmann thrombasthenia

Study on the Clinical Phenotype and Mechanism in Five Chinese Pedigrees with Glanzmann Thrombasthenia

Genetic Confirmation and Identification of Novel Variants for Glanzmann Thrombasthenia and Other Inherited Platelet Function Disorders: A Study by the Korean Pediatric Hematology Oncology Group (KPHOG)

A Novel Homozygous Frameshift Mutation in ITGB3 Causes Glanzmann's Thrombasthenia.

When Glanzmann Thrombasthenia Encounters Antithrombin Deficiency: How Do We Balance the Risk and Benefit of Antithrombotic Therapy?

Molecular mechanisms of Glanzmann thrombasthenia caused by α II b P126H mutation: An in vitro experiment

Molecular analysis of phenotypes and genotypes in three Chinese pedigrees with Glanzmann thrombasthenia

Study of Bernard-Soulier Syndrome Megakaryocytes and Platelets Using Patient-Derived Induced Pluripotent Stem Cells